Market Overview

UPDATE: Canaccord Raises PT to $19.50 on PhotoMedex on Solid Q412 Earnings Beat

Related PHMD
20 Biggest Mid-Day Gainers For Wednesday
Mid-Day Market Update: Twilio Tumbles On Weak Guidance; Pieris Pharma Shares Climb

Canaccord analyst William J. Plovanic published a report on PhotoMedex (NASDAQ: PHMD) that reiterated its Neutral rating and raised the price target from $18.50 to $19.50.

Canaccord reported that, “We reiterate our BUY rating post the release of strong results relative to our and consensus expectations. Revenue results outperformed preannounced results and were paired with a very strong beat on EPS, demonstrating operating leverage capabilities of the business model. Additionally, growth initiatives including geographic expansion for consumer products and increased DTC for psoriasis treatment positions PhotoMedex for continued growth.”

Shares of PhotoMedex closed at $15.89 on Wednesday.

Latest Ratings for PHMD

Nov 2014Canaccord GenuityMaintainsHold
Aug 2014Canaccord GenuityDowngradesBuyHold
May 2014AscendiantDowngradesBuyHold

View More Analyst Ratings for PHMD
View the Latest Analyst Ratings

Posted-In: CanaccordAnalyst Color Price Target Analyst Ratings


Related Articles (PHMD)

View Comments and Join the Discussion!